Oral Anticancer Therapy: Management of Drug Interactions

被引：31

作者：

Rogala, Britny G. ^{[1
]}

Charpentier, Margaret M. ^{[1
]}

Nguyen, Michelle K. ^{[2
]}

Landolf, Kaitlin M. ^{[3
]}

Hamad, Lamya ^{[4
]}

Gaertner, Kelly M. ^{[5
]}

机构：

[1] Univ Rhode Isl, Avedisian Hall,7 Greenhouse Rd, Kingston, RI 02881 USA

[2] New York Presbyterian Hosp, New York, NY USA

[3] UPMC Presbyterian, Pittsburgh, PA USA

[4] Roswell Pk Canc Inst, Buffalo, NY USA

[5] Allegheny Hlth Network, Pittsburgh, PA USA

来源：

JOURNAL OF ONCOLOGY PRACTICE | 2019年 / 15卷 / 02期

关键词：

TYROSINE-KINASE INHIBITORS; CHRONIC LYMPHOCYTIC-LEUKEMIA; PROTON PUMP INHIBITORS; CANCER-PATIENTS; VENOUS THROMBOEMBOLISM; RISK-FACTORS; IBRUTINIB; ANTIDEPRESSANTS; PHARMACOKINETICS; ASPERGILLOSIS;

D O I：

10.1200/JOP.18.00483

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Oral anticancer therapy is increasingly integrated into the care of patients with cancer. Recognition and management of drug-drug interactions (DDIs) is critical to providing efficacious and safe anticancer treatment. DDIs with QTc-prolonging agents, anticoagulants, enzyme inducers and inhibitors, antidepressants, and acid suppressants are commonly encountered with anticancer therapies. Here, we review frequently observed DDIs and outline literature-supported suggestions for their management. (C) 2019 by American Society of Clinical Oncology

引用

页码：81 / +

页数：11